| scholarly article | Q13442814 |
| P50 | author | Catherine A. McCarty | Q37637392 |
| P2093 | author name string | Ronald M Krauss | |
| Richard L Berg | |||
| Russell A Wilke | |||
| James G Linneman | |||
| Chengfeng Zhao | |||
| P2860 | cites work | Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor | Q34310560 |
| Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening | Q34400852 | ||
| P433 | issue | 4 | |
| P921 | main subject | lipoprotein | Q28350 |
| P304 | page(s) | 354-359 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository | |
| P478 | volume | 103 |
| Q37416464 | A common functional promoter variant links CNR1 gene expression to HDL cholesterol level |
| Q35447163 | Cardiovascular pharmacogenomics |
| Q34539676 | Chapter 13: Mining electronic health records in the genomics era. |
| Q37620582 | Characterization of statin dose response in electronic medical records |
| Q42714050 | Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting |
| Q40499193 | HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals |
| Q35844499 | High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome |
| Q34129068 | Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus |
| Q31010852 | Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks |
| Q34348337 | Mapping genes that predict treatment outcome in admixed populations |
| Q26997380 | Pharmacogenomics and cardiovascular disease |
| Q35116507 | Sequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events |
| Q34326946 | The absence of longitudinal data limits the accuracy of high-throughput clinical phenotyping for identifying type 2 diabetes mellitus subjects |
| Q46376996 | The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy |
| Q35478918 | The emerging role of electronic medical records in pharmacogenomics |
| Q34212512 | The oral-systemic personalized medicine model at Marshfield Clinic |
| Q36203536 | The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. |
| Q37172286 | Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity |
Search more.